Zumutor Biologics is a biopharma company that develops biobetters, new biological entities and biosimilars to large antibody structures.
Zumutor Biologics creates product portfolios focused on immuno-oncology. The Company's interest lies in oncology, diabetes and autoimmune disorders.
Zumutor Biologics was founded in 2015, in Bangalore, India, by Kavitha Iyer Rodrigues. The company is based in Woburn, Massachusetts, with an office in Bangalore, Karnataka, India.
Zumutor Biologics' goal is to use next generation antibody technologies to make new biological entities.
Zumutor Biologics has two proprietary Antibody Engineering Platforms to develop novel immunotherapies that target innate immunity and regulate the tumor microenvironment.
Zumutor Biologics engage in cutting edge research and development with proprietary antibody engineering platforms to develop novel combinatorial immuno-oncotherapeutics that target innate immunity and regulation of the Tumour Micro environment.
Zumutor Biologics is backed by Accel Partners, Bharat Innovation Fund, Chiratae Ventures, IDG Ventures SEA and others. The company raised addition $4M from its Series A2 round on Nov 28, 2019. This brings Zumutor's total funding to $20M to date.